LENZ Therapeutics, Inc. (LENZ) NASDAQ
9.67
+0.32(+3.42%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
9.67
+0.32(+3.42%)
Currency In USD
Address
445 Marine View Avenue
Solana Beach, CA 92014
United States of America (the)
Phone
(858) 925-7000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
6
First IPO Date
March 22, 2024
| Name | Title | Pay | Year Born |
| Evert Schimmelpennink | President, CEO, Secretary & Director | 1.07M | 1972 |
| James W. McCollum | Co-Founder & Director | 31,209 | 1955 |
| Shawn Olsson | Chief Commercial Officer | 532,133 | 1983 |
| Daniel R. Chevallard | Chief Financial Officer | 680,368 | 1979 |
| Marc G. Odrich | Chief Medical Officer | 732,250 | 1959 |
| Kris Gambelin | Senior Vice President of Regulatory & Clincal Operations | 0 | N/A |
| David Choromanski | Vice President of Marketing | 0 | N/A |
| Domenick Porfidia | Vice President of Sales | 0 | N/A |
| Melissa Rosness | Senior Vice President of Manufacturing Operations | 0 | N/A |
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.